Condition: Epidermolysis Bullosa (EB) · Sponsor: Paradigm Therapeutics
The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 years old at study entry. There are only 4 site visits by patients with minimal assessments over a 2-month period, and patients completing this study will have the ability to continue receiving SD-101-6.0 at home in an open-label extension study. The drug product and placebo require no special preparation or storage conditions (room temperature).
This description comes directly from the study's public registry record.
Kathleen Watts · 352-586-4083 · Cure@Kapadi.com
Robert P Ryan, PhD · 919-274-0703 · rryan@paradigmtherapeutics.com
Always discuss trial participation with your own doctor first.
| Mission Dermatology | Rancho Santa Margarita, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07482787